Immunome (IMNM) Fundamental Analysis: Revenue, Earnings & Valuation

4.57 / 10

Netural

Fundamental rating is neutral at 4.6/10. Strengths include a high interest coverage ratio (35.1) and positive Asset‑MV. Weaknesses are a –23.2% YoY revenue decline, high current‑liabilities ratio (92%), and elevated cost‑of‑sales (64%).

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score1/3

Weight25.48%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value-23.23

Score0/3

Weight-22.07%

1M Return-4.79%

Inventory turnover ratio

Value103.94

Score2/3

Weight-5.85%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value92.11

Score1/3

Weight-8.19%

1M Return-1.69%

PB-ROE

Value1.67

Score2/3

Weight47.85%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.01

Score2/3

Weight-1.81%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-5.95%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-23.23

Score2/3

Weight0.29%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-5.62%

1M Return-1.13%

Asset-MV

Value-0.55

Score2/3

Weight75.87%

1M Return11.12%

Is IMNM fundamentally strong?

IMNM scores 4.57/10 on fundamentals and holds a Fair valuation at present. Backed by its -52.09% ROE, -3059.99% net margin, -11.52 P/E ratio, 3.86 P/B ratio, and 51.40% earnings growth, these metrics solidify its Netural investment rating.